OncoMatch/Clinical Trials/NCT05351320
WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC
Is NCT05351320 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including WX-0593 Tablets and chemotherapy for non-small cell lung cancer (nsclc).
Treatment: WX-0593 Tablets · chemotherapy — The aim of this trial is to evaluate the safety of WX-0593 combined with concurrent chemoradiotherapy in unresectable, locally advanced non-small cell lung cancer (NSCLC) with activating mutation of ALK or ROS1. This trial consists of two parts. In Part 1, approximately 8 patients will be included and receive WX-0593 maintenance until disease progression or unacceptable toxicity. In Part 2, approximately 32 patients will be included and receive WX-0593 monotherapy for 1-2 cycles and subsequently with concurrent chemoradiation, followed by WX-0593 maintenance until disease progression or unacceptable toxicity.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK activating mutation
Required: ROS1 activating mutation
Disease stage
Required: Stage II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: ALK inhibitor
Has received prior therapy with any ALK TKI
Lab requirements
Blood counts
adequate organ and marrow function
Kidney function
adequate organ and marrow function
Liver function
adequate organ and marrow function
Have adequate organ and marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify